HK1212034A1 - 利培酮的抗體及其用途 - Google Patents

利培酮的抗體及其用途

Info

Publication number
HK1212034A1
HK1212034A1 HK15112825.9A HK15112825A HK1212034A1 HK 1212034 A1 HK1212034 A1 HK 1212034A1 HK 15112825 A HK15112825 A HK 15112825A HK 1212034 A1 HK1212034 A1 HK 1212034A1
Authority
HK
Hong Kong
Prior art keywords
risperidone
antibodies
Prior art date
Application number
HK15112825.9A
Other languages
English (en)
Inventor
Eric Hryhorenko
Banumathi Sankaran
Thomas R Decory
Theresa Tubbs
Linda Colt
Maarten Vliegen
Pieter Rik Haspeslagh
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of HK1212034A1 publication Critical patent/HK1212034A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
HK15112825.9A 2012-08-21 2015-12-30 利培酮的抗體及其用途 HK1212034A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691675P 2012-08-21 2012-08-21
US201361790880P 2013-03-15 2013-03-15
PCT/US2013/055803 WO2014031648A2 (en) 2012-08-21 2013-08-20 Antibodies to risperidone and use thereof

Publications (1)

Publication Number Publication Date
HK1212034A1 true HK1212034A1 (zh) 2016-06-03

Family

ID=50148309

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112825.9A HK1212034A1 (zh) 2012-08-21 2015-12-30 利培酮的抗體及其用途

Country Status (12)

Country Link
US (2) US9664700B2 (zh)
EP (3) EP3462173B1 (zh)
JP (3) JP6339569B2 (zh)
CN (2) CN104737017B (zh)
AU (2) AU2013305887B2 (zh)
CA (1) CA2882594C (zh)
ES (2) ES2870004T3 (zh)
HK (1) HK1212034A1 (zh)
PL (2) PL2888593T3 (zh)
PT (2) PT2888593T (zh)
TR (1) TR201816416T4 (zh)
WO (1) WO2014031648A2 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
ES2666000T3 (es) 2012-08-21 2018-04-30 Janssen Pharmaceutica, N.V. Anticuerpos para aripiprazol y uso de los mismos
CN108484496B (zh) 2012-08-21 2022-03-22 詹森药业有限公司 阿立哌唑半抗原及其在免疫测定中的应用
WO2014031595A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of paliperidone
JP6374387B2 (ja) * 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
US9465041B2 (en) * 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
AU2013305904B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to quetiapine haptens and use thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
WO2016166415A1 (en) 2015-04-13 2016-10-20 Teknologian Tutkimuskeskus Vtt Oy Lateral flow device, assay device and kit and method for analyzing a fluid sample
AU2016372069A1 (en) * 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN106611517B (zh) * 2016-08-12 2020-04-24 简极科技有限公司 一种球类战术演示方法和装置
CN110938072A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种利培酮人工抗原及其制备方法
WO2022226079A1 (en) * 2021-04-20 2022-10-27 Inbios International, Inc. Neutralizing antibodies against sars-cov-2
CN114957456B (zh) * 2022-05-28 2024-03-12 浙江大学医学院附属第一医院 甲型流感病毒血凝素蛋白的单克隆抗体zju-a1a3及其在检测中的应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2184734T3 (es) 1987-04-27 2003-04-16 Inverness Medical Switzerland Dispositivo de prueba analitica para realizar ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
DE69232002T2 (de) 1991-06-07 2002-06-06 Johnson & Johnson Clin Diag Immunoassays unter Verwendung von markierten Hapten-Analogen
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU668159B2 (en) 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CZ293764B6 (cs) 1993-11-19 2004-07-14 Janssen Pharmaceutica N. V. Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
CA2192467C (en) 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
EP1476469B1 (en) * 2002-01-25 2015-11-18 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of c5ar
DE60335428D1 (de) 2002-01-31 2011-02-03 Randox Lab Ltd Immunogene, Antikörper und Konjugate für Ketamin und dessen Metaboliten
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
JP2005533009A (ja) 2002-03-28 2005-11-04 イーライ・リリー・アンド・カンパニー ピペラジン置換されたアリールベンゾジアゼピン類およびそのドーパミン受容体アンタゴニストとしての精神病性障害の処置のための使用
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
WO2004011031A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
MXPA06001938A (es) 2003-08-18 2006-05-17 Lundbeck & Co As H Trans-1-(6-cloro-3-fenilindan-1-il)-3,3-dimetilpiperazina.
CA2538745A1 (en) 2003-09-23 2005-03-31 Fermion Oy Preparation of quetiapine
CN100549004C (zh) 2003-10-01 2009-10-14 阿得罗公司 螺环杂环衍生物及其应用方法
ZA200602347B (en) 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
AU2004298660B2 (en) * 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
GB0328892D0 (en) * 2003-12-12 2004-01-14 Inverness Medical Switzerland Positive signal assay for analytes
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
EP1874350A2 (en) * 2005-04-22 2008-01-09 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US9023993B2 (en) * 2006-10-20 2015-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2008047925A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
JP2010507648A (ja) * 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
JP5450092B2 (ja) 2006-12-29 2014-03-26 アボット・ラボラトリーズ 全血中の分子または薬物の検出のための診断検査
CN101600716A (zh) 2007-01-08 2009-12-09 阿特维斯集团公司 用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
CN101245065B (zh) 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
JP2010540920A (ja) 2007-09-27 2010-12-24 ノバルティス アーゲー 薬物モニタリングアッセイ
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
MX2011003598A (es) 2008-10-14 2011-04-27 Astrazeneca Ab Compuestos heteroaromaticos espirociclicos, fusionados, para el tratamiento de infecciones bacterianas.
EP2347015A4 (en) 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
NZ594071A (en) 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
EP3138854B1 (en) 2009-03-10 2022-01-26 Baylor Research Institute Antibodies against cd40
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
CA2766747C (en) * 2009-07-10 2019-04-02 Innate Pharma Tlr3 binding agents
ES2833035T3 (es) 2009-07-31 2021-06-14 Ascendis Pharma As Hidrogeles biodegradables insolubles en agua a base de polietilenglicol
WO2011021381A1 (ja) * 2009-08-17 2011-02-24 株式会社未来創薬研究所 抗hb-egf抗体を有効成分として含む医薬組成物
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
AU2010336981B2 (en) 2009-12-31 2014-04-10 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
EP2544536B1 (en) 2010-03-11 2018-12-12 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
PT2606070T (pt) * 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CA2843875C (en) 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
AU2012351747B2 (en) 2011-12-15 2016-05-12 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2014028800A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
US9304126B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of quetiapine
AU2013305904B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to quetiapine haptens and use thereof
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
WO2014031587A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of olanzipine
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
JP6131500B2 (ja) * 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドン及びパリペリドンのハプテン
WO2014031595A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of paliperidone
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
ES2666000T3 (es) 2012-08-21 2018-04-30 Janssen Pharmaceutica, N.V. Anticuerpos para aripiprazol y uso de los mismos
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
US9465041B2 (en) 2012-08-21 2016-10-11 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
CN108484496B (zh) 2012-08-21 2022-03-22 詹森药业有限公司 阿立哌唑半抗原及其在免疫测定中的应用
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof

Also Published As

Publication number Publication date
PT3462173T (pt) 2021-04-28
CN104737017A (zh) 2015-06-24
PL3462173T3 (pl) 2021-08-16
CN104737017B (zh) 2017-03-08
WO2014031648A3 (en) 2014-05-01
EP3933406A3 (en) 2022-04-20
EP3462173A1 (en) 2019-04-03
AU2018203561B2 (en) 2020-05-21
EP3462173B1 (en) 2021-03-31
US20170299618A1 (en) 2017-10-19
US9664700B2 (en) 2017-05-30
ES2870004T3 (es) 2021-10-26
CA2882594A1 (en) 2014-02-27
EP2888593A2 (en) 2015-07-01
WO2014031648A2 (en) 2014-02-27
JP2015527367A (ja) 2015-09-17
CN107043424B (zh) 2021-03-16
PT2888593T (pt) 2018-12-12
CA2882594C (en) 2019-07-16
EP3933406A2 (en) 2022-01-05
AU2013305887A1 (en) 2015-03-05
JP6339569B2 (ja) 2018-06-06
US10690686B2 (en) 2020-06-23
PL2888593T3 (pl) 2019-02-28
AU2013305887B2 (en) 2018-02-22
CN107043424A (zh) 2017-08-15
EP2888593B1 (en) 2018-09-19
EP2888593A4 (en) 2016-07-20
AU2018203561A1 (en) 2018-06-07
JP2018127456A (ja) 2018-08-16
US20140057302A1 (en) 2014-02-27
ES2691092T3 (es) 2018-11-23
JP2020143059A (ja) 2020-09-10
TR201816416T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
HK1212034A1 (zh) 利培酮的抗體及其用途
HK1211957A1 (zh) 利培酮半抗原的抗體及其用途
HK1255219A1 (zh) 喹硫平的抗體及其用途
HK1207092A1 (zh) 抗- 抗體及其用途
HK1211958A1 (zh) 帕潘立酮的抗體及其用途
SG11201407099WA (en) Anti-pcsk9 antibodies and use thereof
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1211989A1 (zh) 阿立呱唑的抗體及其用途
HK1212033A1 (zh) 奧氮平的抗體及其用途
HK1211956A1 (zh) 帕潘立酮半抗原的抗體及其用途
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
IL238366A0 (en) Antibodies to interleukin-6 and their uses
HK1209432A1 (zh) 抗鋸齒蛋白抗體及使用方法
GB201208372D0 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF THE APPLICANT FROM JANSSEN PHARMACEUTICA, N.V

Effective date: 20190801

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230818